Mutual of America Capital Management 13F: Cuts ILMN Stake by $11M

Mutual of America Capital Management lowered its stake in Illumina, Inc. ILMN by 72.5% during the quarter, according to a Form 13F filing on October 23, 2026. Illumina shares closed at $269.42 on the day of the filing.

ILMN Illumina, Inc.

$269.42 ▲ +100.54% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Mutual of America's Illumina Position

The institutional investor trimmed its holdings by selling 40,751 shares during the period. The fund ended the quarter with 15,424 shares of the genetic sequencing specialist. That remaining stake held a total reported value of $4,221,240, down significantly from its prior position of 56,175 shares.

Other Institutional Activity in Illumina

Other large money managers also adjusted their holdings in the healthcare company during recent reporting periods. WCM Investment Management, LLC grew its holdings by 283,711 shares, ending with 6,206,701 shares worth about $1,672,209,466. AQR Capital Management, LLC reduced its stake by 436,738 shares to hold 3,544,465 shares valued at $954,949,807. Meanwhile, Primecap Management Company lifted its position by 1,447,330 shares, bringing its total to 3,514,465 shares worth roughly $946,916,780.

Illumina, Inc. Stock Down 4.8%

The stock recently traded around $269.42 as of October 24, 2026, remaining right around its event-day close. The equity trades 12.1% above its 50-day moving average of $240.27 and sits 56.4% higher than its 200-day moving average of $172.30. Illumina shares have traded between a 52-week low of $94.00 and a 52-week high of $309.35.

Recent Earnings

The company posted trailing twelve-month revenue of $4,494,000,128 alongside trailing earnings of $5.10 per share. Illumina generated a net profit margin of 18.3% and delivered a return on equity of 32.3%. The next financial report is scheduled for October 29, 2026.

Insider Buying and Selling at Illumina, Inc.

Company insiders executed several transactions ahead of the filing. Officer Christensen Jakob Wedel sold 1,033 shares on August 18, 2026, at an average price of $191.52 for a total value of $197,840. Director Keith A Meister completed three separate sales, disposing of 679,574 shares on August 21 for $145,556,398, 375,941 shares on August 27 for $85,241,664, and 263,560 shares on September 4 for $57,199,201.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock across October 2026. Guggenheim maintained a buy rating on October 1 and raised its target from $226.00 to $305.00. RBC Capital kept an outperform rating on October 5 while lifting its target from $230.00 to $310.00. Barclays maintained an underweight rating on October 7 with a target moved from $160.00 to $200.00. TD Cowen maintained a hold rating on October 13, raising its target from $210.00 to $270.00. Canaccord Genuity maintained a hold rating on October 19, boosting its target from $205.00 to $300.00. Overall, the stock carries a consensus buy rating from 20 analysts with a mean price target of $245.80.

About Illumina

Illumina, Inc. builds sequencing and array instruments used in genetic and genomic research. Healthcare providers and academic laboratories rely on its platforms to study DNA and RNA variation, supporting clinical diagnostics and life science discovery.

Bottom Line

Investors will look to Illumina's upcoming earnings report on October 29, 2026, for fresh commentary on revenue growth and margin trends. Institutional and insider positioning will remain a focal point following recent large transactions.